The global Oral Antianginal Drugs market size is predicted to grow from US$ 6138 million in 2025 to US$ 7741 million in 2031; it is expected to grow at a CAGR of 3.9% from 2025 to 2031.

Angina pectoris drugs are medications used to manage and alleviate the symptoms of angina pectoris, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. These drugs aim to improve blood flow, reduce the hearts workload, and prevent the occurrence of angina episodes.

Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.

LPI (LP Information) newest research report, the Oral Antianginal Drugs Industry Forecast looks at past sales and reviews total world Oral Antianginal Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Antianginal Drugs sales for 2025 through 2031. With Oral Antianginal Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Antianginal Drugs industry.

This Insight Report provides a comprehensive analysis of the global Oral Antianginal Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oral Antianginal Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Oral Antianginal Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Antianginal Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Antianginal Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Antianginal Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Beta Blockers
    Calcium Antagonists
    Anticoagulants
    Anti-Platelets
    Others

Segmentation by Application:

    Hospitals
    Clinics
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Pfizer Inc.
    Bayer AG
    AstraZeneca
    Gilead Sciences
    Novartis AG
    GlaxoSmithKline Plc.
    Merck & Co., Inc.
    Amgen Inc.
    Eli Lilly and Company
    Otsuka Pharmaceutical Co., Ltd.
    Sanofi S.A.
    Boehringer Ingelheim International GmbH